Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 9 , Pages 660-666 , November 2009

Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment

  • M. Arca

      Affiliations

    • Department of Clinical and Medical Therapy, Unit of Medical Therapy, University La Sapienza of Rome, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 4451354; fax: +39 06 4440290.
    • ,
  • V.M. Cambuli

      Affiliations

    • Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy
    • Department of Clinical Sciences, University of Rome La Sapienza, Rome, Italy
    • ,
  • A. Montali

      Affiliations

    • Department of Clinical and Medical Therapy, Unit of Medical Therapy, University La Sapienza of Rome, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy
    • ,
  • F. Sentinelli

      Affiliations

    • Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy
    • ,
  • E. Filippi

      Affiliations

    • Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy
    • ,
  • F. Campagna

      Affiliations

    • Department of Clinical and Medical Therapy, Unit of Medical Therapy, University La Sapienza of Rome, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy
    • ,
  • F. Quagliarini

      Affiliations

    • Department of Clinical and Medical Therapy, Unit of Medical Therapy, University La Sapienza of Rome, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy
    • ,
  • R. Antonini

      Affiliations

    • Department of Clinical and Medical Therapy, Unit of Medical Therapy, University La Sapienza of Rome, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy
    • ,
  • S. Romeo

      Affiliations

    • Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy
    • ,
  • M.G. Baroni

      Affiliations

    • Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy

Received 25 September 2008 ,Revised 12 November 2008 ,Accepted 13 November 2008.

References 

  1. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet. 2004;13:R149–R160
  2. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case–control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 2003;108:519–523
  3. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003;23:1289–1294
  4. Sniderman AD, Ribalta J, Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases?. Nutr Metab Cardiovasc Dis. 2001;11:259–273
  5. Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;22:274–282
  6. Veerkamp MJ, de Graaf J, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1026–1031
  7. Castro Cabezas M, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160–168
  8. Eurlings PM, Van Der Kallen CJ, Geurts JM, Kouwenberg P, Boeckx WD, De Bruin TW. Identification of differentially expressed genes in subcutaneous adipose tissue from subjects with familial combined hyperlipidemia. J Lipid Res. 2002;43:930–935
  9. Aitman TJ, Godsland IF, Farren B, Crook D, Wong HJ, Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1997;17:748–754
  10. Karjalainen L, Pihlajamäki J, Karhapää P, Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?. Arterioscler Thromb Vasc Biol. 1998;18:1548–1553
  11. Pihlajamäki J, Karjalainen L, Karhapää P, Vauhkonen I, Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2000;20:164–170
  12. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563–2568
  13. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm Res. 2003;60(Suppl. 3):56–59
  14. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  15. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uccida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP activated protein kinase. Nat Med. 2002;8:1288–1295
  16. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived serum protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism. 2003;52:1612–1614
  17. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764–2769
  18. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005;51:578–585
  19. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism. 2004;53:589–593
  20. Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;89:2665–2671
  21. van der Vleuten GM, van Tits LJ, den Heijer M, Lemmers H, Stalenhoef AF, de Graaf J. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile. J Lipid Res. 2005;46:2398–2404
  22. Campagna F, Montali A, Baroni MG, Antonini TM, Ricci G, Antonini R, et al. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism. 2002;51:1298–1305
  23. Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Petramala L, et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hypercholesterolemia. Metabolism. 2007;56:1534–1541
  24. Matthews DR, Hasker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419
  25. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47(10):1643–1649
  26. Koh KK, Han SH, Quon MJ, Ahn JY, Shin EK. Metabolic effects of fenofibrate in primary hypertriglyceridemic patients. Diabetes Care. 2005;28:1419–1424
  27. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kim JA, et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006;29:195–201
  28. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649–1653
  29. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687–3692
  30. ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest. 2005;35:558–564
  31. Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis. 2007;193:449–451

PII: S0939-4753(08)00232-9

doi: 10.1016/j.numecd.2008.11.008

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 9 , Pages 660-666 , November 2009

Article Tools

* Image Usage & Resolution